FDA approves AstraZeneca's Imfinzi with enfortumab vedotin for bladder cancerNov 16Regulatory decisionAstraZenecadurvalumab
Lilly posts Phase 2b retatrutide renal results; registers tersolisib kidney PK studyNov 13Weekly roundup, 10 itemsabemaciclibanastrozole
FDA accelerated approval covers Padcev plus Keytruda in urothelial carcinomaNov 9Regulatory decisionenfortumab vedotinMerck & Co., Inc.
Adagene completes enrollment in Phase 2 muzastotug dose-optimization trial for MSS colorectal cancerNov 9Trial updateAdagene Inccisplatin
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
Merck collaborator posts pancreatic cancer results; new MK-1045, COPD trial records surfaceNov 6Weekly roundup, 14 itemsDaiichi SankyoensifentrineUpdated
Regeneron-linked TOP2201 posts results; NeoSTOP-IT terminated, DEUTERON completedNov 5Weekly roundup, 7 itemsafliberceptALN-CIDEBUpdated
Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
AstraZeneca's FORTUNA misses in NASH as ARTEMIS kidney trial ends for lack of efficacyOct 30Weekly roundup, 8 itemsalbuterol sulfate and budesonideAstraZenecaUpdated
Rafael's Cyclo Therapeutics files NDA for remibetadex in Niemann-Pick Disease Type COct 29Regulatory decisionRafael Holdings, Inc.Updated
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completesOct 16Weekly roundup, 11 itemsacalabrutinibAstraZenecaUpdated
Genentech lists Phase Ib KRAS G12D trial; Roche-sponsored DLBCL study shows updateOct 9Weekly roundup, 9 itemsalectinibcisplatinUpdated
AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adultsOct 2Weekly roundup, 6 itemsacalabrutinibanifrolumab-fnia
AbbVie registers Phase 1 trial comparing upadacitinib, tofacitinib, baricitinib in healthy adultsSep 30Weekly roundup, 4 itemsABBV-722AbbVie
Nanobiotix updates on JNJ-1900 (NBTXR3) trials, FDA-cleared protocol change, and cash into 2029Sep 24Quarterly updateNanobiotix S.A.
Fennec reports Phase 2 PEDMARK data from Japan met primary endpoint at SIOP 2026Sep 17Clinical readoutFennec Pharmaceuticals Inc.sodium thiosulfate
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PGAug 24Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Incyte-linked filings this week: FIGHT-302 results posted, new academic pancreatic trial listedAug 14Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Merck posts Q2 loss on Terns charge, raises full-year sales outlookAug 4Quarterly updateMerck & Co., Inc.
Bicycle Therapeutics reports Q2 2026 pipeline progress, cash into 2030Jul 30Quarterly updateBicycle Therapeutics Plc
Molecular Partners reports progress in Phase 2 TACTIC trial of MP0317 for cholangiocarcinomaJul 20Clinical readoutMolecular Partners AG
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin